The Ultimate Guide to Blincyto

• INDICATION AND USAGE

Blincyto is a cancer drug that has a potent active ingredient, Blinatumomab. It is used to treat B-precursor acute lymphoblastic leukemia, a blood cancer that is called in patients above the age of one year. It is used by those patients whose cancer has relapsed or has not improved with previous treatment. Healthcare professionals uAs part of ‘consolidation therapy,’ to improve the diminution of cancer, Blincyto is used. Its usage is also accompanied in patients who have the protein CD19 on their cancer cells and are ‘Philadelphia-chromosome-negative’ (Ph-negative). It states that the patient’s cancer cells do not have an abnormal Philadelphia chromosome.

Various suppliers can purchase it, and you can also buy Blincyto online from various websites like Indiapharmanetwork. in, Indiamart.com, and more. Indian Pharma Network is among the trusted and most reliable suppliers of generic drugs.

•  Dosage and Preparation

BLINCYTO is available in injections as 35 mcg lyophilized powder that comes in a single-dose vial for administration. Blincyto's price in India is pocket friendly, so it can be easily obtained and only be purchased with a prescription. Treatment should be started by a medical professional with expertise in treating patients with blood cancers. Before initiating the treatment, it is mandatory to measure body weight, as dose calculation is based on weight. A pump device gives it intravenously only by dripping it into the vein.

For reconstitution, the walls of BLINCYTO are added directly with 3 mL of preservative-free Sterile Water for Injection USP, and the resulting final concentration is 12.5 mcg/mL. Gently swirl the prepared infusion avoiding the excess foam.

• Administration

Before administration, check for any particulate matter or discoloration; if observed, the prepared formulation needs to be avoided and should never be used. The prepared infused bag must be continuously induced after 24 or 48 hours of preparation. 

Blincyto is infused continuously for four weeks as part of the treatment cycle. An interval segregates each cycle after a two-week treatment. If the benefits outweigh the risks, patients with no signs of cancer after two cycles are treated with an additional three cycles of BLINCYTO.

The drug is available in India for use. It can be supplied by approved generic and innovative medication suppliers, and We are among the most reliable suppliers to buy  BLINCYTO 38.5 mcg at economical prices. To know more about the drug, contact us at our Toll-free number +91 93100 90915.

• Method of Action 

The active substance in Blincyto is Blinatumomab, an antibody designed to attach to a protein (CD19) found on B cells, including ALL cells because it is a bispecific CD19-directed CD3 T-cell. It also attaches to a protein (CD3) in T cells. The drug is produced in Chinese hamster ovary cells. Attaching to CD3, therefore, acts as a ‘bridge’ that brings T cells and B cells together and causes the T cells to release substances that eventually kill the cancerous B cells.

People with blood cancer can get this medicine against a prescription from any of the suppliers at economical prices as BLINATUMOMAB price is pocket friendly and reasonable in India. 

• Adverse Reactions and Side Effects

It is known that there are specific side effects accompanied by BLINCYTO injection, which can be mild or life-threatening. The most common adverse reactions which are seen after using BLINCYTO are infections, fever, infusion-related reactions, headache, febrile neutropenia, constipation, nausea, diarrhea, vomiting, anemia ( low red blood cell counts), leucopenia (low levels of white blood cell), oedema (swelling because of fluid retention), neutropenia (low levels of neutrophils, a type of white blood cell), thrombocytopenia (low platelet count), blood tests showing changes in liver function, tremor (shaking), back pain, chills, etc.

The most serious reactions associated with BLINCYTO include neutropenia with or without fever, infections, cytokine release syndrome, and tumor lysis syndrome.

• Drug Interactions

There are no as such prior formal drug interaction studies conducted with BLINCYTO. But it is known that starting the treatment of BLINCYTO causes transient release of cytokines that may suppress CYP450 enzymes. Patients with a narrow therapeutic index and receiving concomitant CYP450 substrates during the first 9 days of the first cycle and the first 2 days of the second cycle have the highest drug-drug interaction risk. In these patients, monitor for drug concentrations (e.g., cyclosporine) and toxicity (e.g., warfarin). If needed, adjust the dose of the concomitant drug.

• Use in a specific population

 Pregnancy- From some animal studies, it is found that BLINCYTO may cause fetal harm. When administered to a pregnant woman, it can cause B-cell lymphocytopenia in the fetus according to their action method. But there is no data on the use of BLINCYTO in pregnant women, but due to its capability of crossing the placental barrier shown in animal studies, it is advised to pregnant women not to use it as it may cause potential risk to a fetus. 

It is readily available, and you can buy the product in the market after having a valid prescription and knowing all the side effects. 

Effect on Lactation- There is no information regarding the presence of Blinatumomab which is an active ingredient of BLINCYTO in human milk, but it is advised to mother patients not to breastfeed during and for at least 48 hours after treatment with BLINCYTO.

• STORAGE

BLINCYTO is stored in cold or frozen places, and each package has one BLINCYTO single-dose vial and one intravenous Solution stabilizer. It is mentioned clearly that the IV Solution Stabilizer should not be used to reconstitute BLINCYTO. The original packages are stored and refrigerated at a temperature of 2°C to 8°C (36°F to 46°F), and they should be protected from light until the time of use. It should be stored and transported at 2°C to 8°C (36°F to 46°F) conditions. It is Shipped in packaging that has been validated to maintain the temperature of the contents at 2°C to 8°C (36°F to 46°F).

Storing and transporting BLINCYTO requires an ideal cool temperature, and the Indian pharma network has expertise in cold chains, so the drug is exported more safely and efficiently. We serve our patients the best thing possible,

• DESCRIPTION

The drug is produced in Chinese hamster ovary cells. Blinatumomab contains 504 amino acids with a molecular weight of approximately 54 kilodaltons. Each package of BLINCYTO comprises 1 vial BLINCYTO and 1 vial IV Solution Stabilizer. The drug is supplied in a single-dose vial as a white to off-white lyophilized powder, which is sterile and preservative-free and to be used intravenously. 

Each single-dose vial of BLINCYTO has a 35 mcg drug, and the injection price is comparatively lower and reasonable in the Indian market.  

• Composition

As far as its composition is concerned, it also contains citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. After reconstitution with 3 mL of preservative-free Sterile Water for Injection, the resulting concentration is 12.5 mcg/mL blinatumomab. Intravenous Solution Stabilizer is supplied in a single-dose vial which is sterile, preservative-free, colorless to the slightly yellow, straightforward solution. Citric acid monohydrate (52.5 mg), lysine hydrochloride (2283.8 mg), polysorbate 80 (10 mg), and sodium hydroxide to adjust pH to 7.0, and water for injection are added to each single-dose vial of IV Solution Stabilize.